amorolfine nail lacquer — Competitive Intelligence Brief

amorolfine nail lacquer (amorolfine nail lacquer) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifungal. Area: Dermatology.

phase 3 Antifungal Ergosterol synthesis Dermatology Small molecule

Target snapshot

amorolfine nail lacquer (amorolfine nail lacquer) — Novartis. Amorolfine nail lacquer works by inhibiting the growth of fungi on the nail plate and nail bed.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
amorolfine nail lacquer TARGET	amorolfine nail lacquer	Novartis	phase 3	Antifungal	Ergosterol synthesis
Vivjoa	OTESECONAZOLE	Mycovia Pharms	marketed	Azole Antifungal [EPC]	Cytochrome P450 3A4	2022-01-01
Brexafemme	IBREXAFUNGERP CITRATE	GSK	marketed	Triterpenoid Antifungal		2021-01-01
Brexafemme	IBREXAFUNGERP	GSK	marketed	Triterpenoid Antifungal		2021-01-01
Cresemba	ISAVUCONAZONIUM	Astellas Pharma	marketed	Azole Antifungal	ATP-binding cassette sub-family G member 2	2015-01-01
Jublia	EFINACONAZOLE	Bausch Health	marketed	Azole Antifungal [EPC]		2014-01-01
Luzu	LULICONAZOLE	Bausch Health	marketed	Azole Antifungal [EPC]		2013-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifungal class)

1. Cidara Therapeutics Inc. · 1 drug in this class
2. Drugs for Neglected Diseases · 1 drug in this class
3. Fernanda P Silveira, MD, MS · 1 drug in this class
4. LI YAN · 1 drug in this class
5. Novartis · 1 drug in this class
6. Polichem S.A. · 1 drug in this class